Oct 26, 2026
•
3 min read
American Express delivered record revenue, raised its outlook and saw credit quality improve. So why did shares slide? Investors are looking past strong fundamentals to broader macroeconomic worries and softer commercial spending.
Oct 25, 2026
Cologuard is driving Abbott’s diagnostics growth, but cautious guidance, a planned nutrition spinoff and technical pressure have investors selling the stock.
Oct 24, 2026
Meta’s Q3 rebound showed strong sales, upbeat guidance, and early momentum for its Muse AI agent. But investors will be watching 2027 capital spending and AI revenue closely.
Oct 23, 2026
While pure-play drone stocks have plunged, these four companies are taking a different path through counter-drone technology, autonomy software, and critical components.
Oct 22, 2026
Meta’s Muse AI launch has reignited investor enthusiasm, but upcoming earnings must prove the momentum is real. A $10 billion legal charge, soaring AI spending, and 2026 guidance will put that comeback to the test.
Oct 21, 2026
With roughly 65% of announced projects at risk of never being built, the real AI infrastructure winners may be the companies securing power, permits, and tenants—not just funding.
Oct 20, 2026
Meta’s Muse Wonder models rank among the AI industry’s most capable, challenging offerings from OpenAI and Alphabet. Their premium pricing and subscription strategy could help turn Meta’s AI progress into revenue.
Oct 19, 2026
Neutron’s latest delay sent Rocket Lab shares below a key technical level, but Wall Street still sees substantial upside. Now, the company must prove its execution—and get the rocket flying in 2027.
Oct 18, 2026
SpaceX’s push to strengthen Starlink Mobile’s indoor coverage adds a fresh competitive threat to AST SpaceMobile. Downgrades, lawsuits, heavy cash burn and repeated earnings misses are piling on the pressure.
Oct 17, 2026
Intel is targeting cost-conscious enterprises with a new air-cooled AI chip built for efficient inference. But as its foundry overhaul racks up billions in losses, the company needs Crescent Island to turn promise into profitable growth.
Oct 16, 2026
Navitas is betting on gallium nitride and NVIDIA-powered infrastructure to solve AI data centers’ growing power demands. Can its high-voltage pivot deliver growth before valuation and profitability concerns catch up?
Oct 15, 2026
OTTAVA gives Johnson & Johnson a new growth engine as solid Q3 results and a resilient balance sheet support its dividend and long-term upside.
Oct 14, 2026
As U.S. efforts to build a domestic rare-earth supply chain accelerate, MP Materials, Energy Fuels, and NioCorp offer distinct ways to benefit—from established production to high-risk growth potential.
Oct 13, 2026
Utilities are showing early signs of a bottom as XLU rebounds from a 52-week low. Here’s why NextEra Energy and Southern Company could offer two distinct ways to play a sector recovery.
Oct 12, 2026
Upcoming clinical, regulatory, and commercial milestones could reignite these battered biotech stocks—but investors must weigh triple-digit potential against significant development risks.
Oct 11, 2026
Tilray is building momentum through booming beverage sales and expanding international medical cannabis operations. Its growth strategy is gaining traction without relying on U.S. legalization.
Oct 10, 2026
A 16% pullback has little to do with InvenTrust’s solid operating performance and growing dividend. With analysts seeing nearly 18% upside, the REIT may offer an attractive entry point—provided investors can stomach rising leverage.
Oct 9, 2026
Disney is licensing select titles to Netflix to turn reach into revenue, signaling a new era of flexible exclusivity. The deal shows how cash flow—not platform control alone—is reshaping streaming.
Oct 8, 2026
Curaleaf’s 25% richer offer for Aurora Cannabis intensifies the race to consolidate the sector’s undervalued assets. With Schedule III tax relief reshaping cannabis economics, investors are watching whether strategic acquisitions can unlock a broader industry turnaround.
Oct 7, 2026
Insiders are cashing in on Aspen Aerogels, Workday, and Everpure—but strong business results could mean their sales aren’t a warning sign. Here’s what investors should know before following suit.
Oct 6, 2026
As AI compute prices threaten data-center returns, the real opportunity may lie with companies solving the industry’s power bottleneck. These four energy stocks offer faster access to electricity through behind-the-meter generation and geothermal technology.
Oct 5, 2026
Strong sales and ambitious expansion are colliding with rising debt, thin margins, and a battered stock price. Upcoming earnings and Investor Day could determine whether First Watch is a bargain—or a warning sign.
Oct 4, 2026
McDonald’s stock has plunged into deeply oversold territory, but AI-pricing concerns and key support levels could determine whether this is a buying opportunity—or a falling knife.
Oct 3, 2026
The $5.7 billion award won’t threaten Apple’s balance sheet—but a recurring royalty on iPhones and Apple Watches could squeeze margins for years. Investors are watching the appeal closely.
Oct 2, 2026
Shares are down 19% despite solid earnings, accelerating professional sales and a bullish long-term outlook. But a premium valuation and softer DIY traffic leave investors weighing quality against risk.
